Literature DB >> 7773226

High-dose melphalan allows durable engraftment of allogeneic bone marrow.

K van Besien1, H Demuynck, C F Lemaistre, M A Bogaerts, R Champlin.   

Abstract

Conditioning regimens for allogeneic bone marrow transplantation are designed to eradicate malignant cells and to provide sufficient immunosuppression for engraftment of donor marrow. Total body irradiation and high-dose cyclophosphamide are the most established immunosuppressive agents used for this purpose. It is uncertain whether other alkylating agent-based conditioning regimens are sufficiently immunosuppressive to allow engraftment of allogeneic marrow. We report four patients who had prompt engraftment after conditioning with melphalan-based chemotherapy regimens (BEAM or busulfan/melphalan). Two patients survived without disease for a prolonged period, indicating that these melphalan regimens are sufficiently immunosuppressive to allow sustained engraftment and donor hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773226

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Cord blood chimerism and relapse after haplo-cord transplantation.

Authors:  Koen van Besien; Nebu Koshy; Usama Gergis; Sebastian Mayer; Melissa Cushing; Hannah Rennert; Ronit Reich-Slotky; Tomer Mark; Roger Pearse; Adriana Rossi; Adrienne Phillips; Liljana Vasovic; Rosanna Ferrante; Yen-Michael Hsu; Tsiporah Shore
Journal:  Leuk Lymphoma       Date:  2016-06-23

2.  Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.

Authors:  Koen van Besien; Rangesh Kunavakkam; Gaby Rondon; Marcos De Lima; Andrew Artz; Betul Oran; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2009-05       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.